nhia logo

Quick Links
Search NHIA.org



Counce J. Home infusion and specialty pharmacy: A marriage whose time has come? 2005:11(1):16-20.

Counce J. Specialty pharmacy from pipeline to payer perspectives: NHIA executive conference explores multiple dimensions of this growing market.2007:13(3);31-4.

Davydov L. Biosimilars and other drugs in today's development pipeline. 2016;22(5):S1-S16.

Deitz-Lovett K. Managing chemotherapy-induced anemia: Supportive care plan for home infusion therapy. 2006.12(6):S1-S8.

Epperson LA and Williams J. Biotherapy: Operationalizing delivery of care while managing risk. 2009:15(2);23-9.

Epstein D. Oncology update: New trends for home care practice. 2001;7(5):22-5.

Flores K. Ambulatory infusion suites: Appropriate therapies. 2005.11(2):22-32.

Franklin D. Operationalizing Complex Therapies: A Business-Focused Approach. 2009:15(2);48-51.

Lima HA. Von Willebrand disease: Diagnosis and treatment in the home care setting. 2006. 12(2):S1-S12.

Meaux N and Siefert L. Managing risk in the increasingly complex home care environment. 2009:15(2);36-40.

Mendelsohn C and Riley P. IGIV fundamentals for home care and alternate site therapy. 2003;9(6):35-8.

Mohler L. Looking down the pipeline: New drugs and biologicals for 2006. 2006:12(1):21-3.

Nowobilski-Vasilios A. New drugs and biologicals 2001-2002: A review for home care practitioners. 2002;8(4):32-42.

Panella-Spangler P. New drug review for 2001;7(5):14-7.

Patel R. Assessing business opportunities in specialty infusion. 2013;19(3):39-44.

Siegel J. IGIV: Uses in autoimmune diseases. 2004.10(5):S1-S8.

Speidel K. Subcutaneous administration of immunoglobulin replacement therapy in the home care setting. 2006. 12(3):S1-S8.

Sullivan C. New parenteral drugs and biologics—2014: The essentials. Supplement to INFUSION.2015;21(4):S1-S16.

Werner K. Exciting new IGIV research presented at the 5th international symposium of IGIV. 2004;10(1):33-7.